B&K Corp Ltd

02396

Company Profile

  • Business description

    B&K Corp Ltd is a China-based biopharmaceutical company committed to developing therapies with an emphasis on protein drugs for indications with medical needs and market opportunities. The company prominently focuses on the discovery, development and commercialization of therapies for wound healing, currently PDGF drugs. Its pipeline consisted of ten candidates, seven of which are PDGF candidates, including two Core Products, namely Pro-101-1 for the treatment of thermal burns and Pro-101-2 for the treatment of DFUs, which are rhPDGF-BB drugs. The company operates in a single reportable segment: the research and development of biopharmaceutical products. Geographically, the company generates all its revenue from Chinese Mainland.

  • Contact

    No. 19 Qinling Road, Xiexin Center
    Room 1507, Building 1
    Laoshan District
    Shandong Province
    Qingdao
    CHN

    http://www.huarenshengwu.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    100

Stocks News & Analysis

stocks

Undervalued ASX healthcare provider

Solid demand profile for global leader.
stocks

SpaceX: What investors need to know about its enormous upcoming IPO

Morningstar launches research coverage of SpaceX.
stocks

Fair value lifts for toll road operator as Aussie fuel supply steadies

An Australian fuel shortage is becoming increasingly unlikely, a relief for ASX toll road operator.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,966.0017.100.19%
CAC 408,209.0962.500.77%
DAX 4025,124.17121.130.48%
Dow JONES (US)51,193.88115.000.23%
FTSE 10010,373.5134.560.33%
HKSE26,038.32640.142.52%
NASDAQ27,107.1520.350.08%
Nikkei 22566,734.24200.09-0.30%
NZX 50 Index13,170.7173.84-0.56%
S&P 5007,610.0510.090.13%
S&P/ASX 2008,724.4017.700.20%
SSE Composite Index4,075.1017.360.43%

Market Movers